Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lyrica Reviewer Concerns On Vision, Skin Led To Consults With Top FDA Staff

Executive Summary

Top CDER officials moderated the primary reviewers' inclination to delay approval of Pfizer's Lyrica (pregabalin) until more data on dermatologic and visual effects better characterized the drug's risks, review documents show
Advertisement

Related Content

Mircera Reviewers Turned To Top-Level FDA Briefing With CRP Concerns
Mircera Reviewers Turned To Top-Level FDA Briefing With CRP Concerns
Pfizer Launch Plans For Lyrica Fibromyalgia Approval Include Patient Groups
Pfizer Launch Plans For Lyrica Fibromyalgia Approval Include Patient Groups
Pfizer Lyrica Launch Awaits Controlled Substance Scheduling
Pfizer Lyrica Launch Awaits Controlled Substance Scheduling
Advertisement
UsernamePublicRestriction

Register

PS047497

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel